Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Thomas

Showing results (621-630 of 792) with videos related to

Pageof 80
Sort By:
Obstetrics and Gynecology|September 4, 2007
Contraceptive efficacy of a novel spermicidal microbicide used with a diaphragm: a randomized controlled trialKurt T Barnhart, Michael J Rosenberg, H Trent MacKay, et al.
International Journal of Cancer|March 19, 2015
Non-small cell lung cancer is characterized by dramatic changes in phospholipid profilesEyra Marien, Michael Meister, Thomas Muley, et al.
Journal of Comparative Effectiveness Research|January 21, 2025
MOMENT registry: Patients with advanced non-small-cell lung cancer harboring <i>MET</i> exon 14 skipping treated with systemic therapyMichael Thomas, Petros Christopoulos, Wade T Iams, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancerThomas Wehler, Michael Thomas, Christian Schumann, et al.
Clinical Lung Cancer|January 27, 2018
Generation of a New Disease-specific Prognostic Score for Patients With Brain Metastases From Small-cell Lung Cancer Treated With Whole Brain Radiotherapy (BMS-Score) and Validation of Two Other IndicesDenise Bernhardt, Laila König, Sophie Aufderstrasse, et al.
Lung Cancer (Amsterdam, Netherlands)|April 10, 2012
The gefitinib long-term responder (LTR)--a cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP)Sandra Gottschling, Esther Herpel, Wilfried E E Eberhardt, et al.
Clinical and Translational Radiation Oncology|December 9, 2024
Fractionated stereotactic radiotherapy of brainstem metastases - Clinical outcome and prognostic factorsAnna Krämer, Laura Hahnemann, Fabian Schunn, et al.
The European Respiratory Journal|March 21, 2015
Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancerMichael Thomas, Jürgen Fischer, Stefan Andreas, et al.
Frontiers in Oncology|December 18, 2020
Consolidation Immunotherapy After Platinum-Based Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer-Cross-Sectional Study of Eligibility and Administration RatesTanja Eichkorn, Farastuk Bozorgmehr, Sebastian Regnery, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 23, 2017
Pulse duration settings in subthalamic stimulation for Parkinson's diseaseFrank Steigerwald, Lars Timmermann, Andrea Kühn, et al.
Pageof 80

Showing results (621-630 of 792) with videos related to

Sort By:
Pageof 80
Obstetrics and Gynecology|September 4, 2007
Contraceptive efficacy of a novel spermicidal microbicide used with a diaphragm: a randomized controlled trialKurt T Barnhart, Michael J Rosenberg, H Trent MacKay, et al.
International Journal of Cancer|March 19, 2015
Non-small cell lung cancer is characterized by dramatic changes in phospholipid profilesEyra Marien, Michael Meister, Thomas Muley, et al.
Journal of Comparative Effectiveness Research|January 21, 2025
MOMENT registry: Patients with advanced non-small-cell lung cancer harboring <i>MET</i> exon 14 skipping treated with systemic therapyMichael Thomas, Petros Christopoulos, Wade T Iams, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancerThomas Wehler, Michael Thomas, Christian Schumann, et al.
Clinical Lung Cancer|January 27, 2018
Generation of a New Disease-specific Prognostic Score for Patients With Brain Metastases From Small-cell Lung Cancer Treated With Whole Brain Radiotherapy (BMS-Score) and Validation of Two Other IndicesDenise Bernhardt, Laila König, Sophie Aufderstrasse, et al.
Lung Cancer (Amsterdam, Netherlands)|April 10, 2012
The gefitinib long-term responder (LTR)--a cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP)Sandra Gottschling, Esther Herpel, Wilfried E E Eberhardt, et al.
Clinical and Translational Radiation Oncology|December 9, 2024
Fractionated stereotactic radiotherapy of brainstem metastases - Clinical outcome and prognostic factorsAnna Krämer, Laura Hahnemann, Fabian Schunn, et al.
The European Respiratory Journal|March 21, 2015
Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancerMichael Thomas, Jürgen Fischer, Stefan Andreas, et al.
Frontiers in Oncology|December 18, 2020
Consolidation Immunotherapy After Platinum-Based Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer-Cross-Sectional Study of Eligibility and Administration RatesTanja Eichkorn, Farastuk Bozorgmehr, Sebastian Regnery, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 23, 2017
Pulse duration settings in subthalamic stimulation for Parkinson's diseaseFrank Steigerwald, Lars Timmermann, Andrea Kühn, et al.
Pageof 80